Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. AKRO, ADMA, PCVX, KRYS, RYTM, CYTK, PTCT, ZLAB, ACAD, and MRUSShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Akero Therapeutics ADMA Biologics Vaxcyte Krystal Biotech Rhythm Pharmaceuticals Cytokinetics PTC Therapeutics Zai Lab ACADIA Pharmaceuticals Merus Akero Therapeutics (NASDAQ:AKRO) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends. Do analysts rate AKRO or CALT? Akero Therapeutics currently has a consensus target price of $82.50, indicating a potential upside of 59.98%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in AKRO or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, AKRO or CALT? Akero Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Which has stronger valuation and earnings, AKRO or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$1.95-26.45Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Is AKRO or CALT more profitable? Akero Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Akero Therapeutics' return on equity of -15.19% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.19% -13.97% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the media refer more to AKRO or CALT? In the previous week, Akero Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Akero Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Akero Therapeutics' average media sentiment score of 0.59 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akero Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral SummaryAkero Therapeutics beats Calliditas Therapeutics AB (publ) on 9 of the 15 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$879.82M$5.62B$9.10BDividend YieldN/A4.84%5.24%4.00%P/E Ratio-21.621.3828.1320.27Price / Sales0.74239.36428.6398.72Price / CashN/A17.6937.4658.16Price / Book37.746.588.045.49Net Income-$43.96M-$23.83M$3.18B$250.45M7 Day PerformanceN/A1.59%3.62%4.78%1 Month PerformanceN/A12.08%4.05%7.67%1 Year Performance1.27%4.39%30.00%16.43% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AKROAkero Therapeutics3.4039 of 5 stars$53.36-5.0%$82.50+54.6%+107.6%$4.48BN/A-27.3630Insider TradeADMAADMA Biologics3.956 of 5 stars$18.21+0.3%$27.67+51.9%+50.4%$4.34B$426.45M21.42530Positive NewsPCVXVaxcyte1.8217 of 5 stars$32.51-0.2%$136.50+319.9%-56.2%$4.20BN/A-8.15160News CoveragePositive NewsKRYSKrystal Biotech4.6822 of 5 stars$137.46-1.0%$211.13+53.6%-25.3%$4.01B$290.52M33.04210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionRYTMRhythm Pharmaceuticals3.1845 of 5 stars$63.19+0.7%$77.31+22.3%+86.1%$3.99B$130.13M-22.49140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCYTKCytokinetics4.0728 of 5 stars$33.04-0.4%$70.92+114.7%-34.3%$3.96B$18.47M-6.25250PTCTPTC Therapeutics4.3456 of 5 stars$48.84-2.0%$65.00+33.1%+46.2%$3.95B$806.78M7.501,410ZLABZai Lab3.0694 of 5 stars$34.97+0.7%$54.28+55.2%+83.5%$3.86B$398.99M-14.041,869Gap UpACADACADIA Pharmaceuticals4.6402 of 5 stars$21.57-2.5%$27.88+29.2%+18.9%$3.70B$957.80M15.74510Analyst RevisionMRUSMerus1.892 of 5 stars$52.60-0.7%$84.64+60.9%-2.4%$3.67B$36.13M-12.8937News CoverageAnalyst UpgradeInsider Trade Related Companies and Tools Related Companies Akero Therapeutics Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives PTC Therapeutics Alternatives Zai Lab Alternatives ACADIA Pharmaceuticals Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALT Stock Alerts